FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Frans Rutten

Research Profile

Activities & Behaviors

Geographic Areas

Netherlands

Concepts & Ideas

Procedures

Health Services Research

Physiology

Decision Making

Co-author Network

Publications

TOP 3
Ana Bobinac; Frans F H Rutten; N J A van Exel; Werner B F Brouwer
Inquiry into the relationship between equity weights and the value of the QALY.
Siok Swan Tan; Frans F H Rutten; C A M Bouwmans; Leona Hakkaart-van Roijen
Update of the Dutch Manual for Costing in Economic Evaluations.
Ana Bobinac; Frans F H Rutten; N J A van Exel; Werner B F Brouwer
GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Frans Rutten (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Ana Bobinac; Frans F H Rutten; N J A van Exel; Werner B F Brouwer
Inquiry into the relationship between equity weights and the value of the QALY.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(8):1119-26.
2012: Siok Swan Tan; Frans F H Rutten; C A M Bouwmans; Leona Hakkaart-van Roijen
Update of the Dutch Manual for Costing in Economic Evaluations.
International journal of technology assessment in health care 2012;28(2):152-8.
2012: Ana Bobinac; Frans F H Rutten; N J A van Exel; Werner B F Brouwer
GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.
Journal of health economics 2012;31(1):158-68.
2011: Siok Swan Tan; Frans F H Rutten; Leona Hakkaart-van Roijen
Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.
Journal of evaluation in clinical practice 2011;17(6):1094-101.
2011: Tim A Kanters; Frans F H Rutten; Nadine A M E van der Beek; Ans T Van Der Ploeg; M L C Hagemans; L Hakkaart
Burden of illness of Pompe disease in patients only receiving supportive care.
Journal of inherited metabolic disease 2011;34(5):1045-52.
2011: Ana Bobinac; N Job A van Exel; Frans F H Rutten; Werner B F Brouwer
Health effects in significant others: separating family and care-giving effects.
Medical decision making : an international journal of the Society for Medical Decision Making 2011;31(2):292-8.
2011: Adri Steenhoek; Margreet G Franken; Marc A Koopmanschap; Frans F H Rutten
[New drugs: money-back guarantee?].
Nederlands tijdschrift voor geneeskunde 2011;155():A2042.
2010: Ana Bobinac; N J A van Exel; Frans F H Rutten; Werner B F Brouwer
Willingness to pay for a quality-adjusted life-year: the individual perspective.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2010;13(8):1046-55.
2010: Werner B F Brouwer; Frans F H Rutten
The efficiency frontier approach to economic evaluation: will it help German policy making?
Health economics 2010;19(10):1128-31.
2010: David R Rappange; Werner B F Brouwer; Frans F H Rutten; Pieter H M van Baal
Lifestyle intervention: from cost savings to value for money.
Journal of public health (Oxford, England) 2010;32(3):440-7.
2010: Ana Bobinac; N Job A van Exel; Frans F H Rutten; Werner B F Brouwer
Caring for and caring about: disentangling the caregiver effect and the family effect.
Journal of health economics 2010;29(4):549-56.
2010: Kirsten M van Steenbergen-Weijenburg; Lars de Vroege; Robert R Ploeger; Jan W Brals; Martijn G Vloedbeld; Thiemo F Veneman; Leona Hakkaart-van Roijen; Frans F H Rutten; Aartjan T F Beekman; Christina van der Feltz-Cornelis
Validation of the PHQ-9 as a screening instrument for depression in diabetes patients in specialized outpatient clinics.
BMC health services research 2010;10():235.
2010: Kirsten M van Steenbergen-Weijenburg; Christina van der Feltz-Cornelis; Eva K Horn; Harm W J van Marwijk; Aartjan T F Beekman; Frans F H Rutten; Leona Hakkaart-van Roijen
Cost-effectiveness of collaborative care for the treatment of major depressive disorder in primary care. A systematic review.
BMC health services research 2010;10():19.
2010: David S Cobden; Louis Niessen; Charles E Barr; Frans F H Rutten; W Ken Redekop
Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2010;13(1):138-47.
2008: Carmen Galani; Frans F H Rutten
Self-reported healthcare decision-makers' attitudes towards economic evaluations of medical technologies.
Current medical research and opinion 2008;24(11):3049-58.
2008: Carmen Galani; Maiwenn Al; Heinz Schneider; Frans F H Rutten
Uncertainty in decision-making: value of additional information in the cost-effectiveness of lifestyle intervention in overweight and obese people.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2008;11(3):424-34.
2008: Werner B F Brouwer; Anthony J Culyer; N Job A van Exel; Frans F H Rutten
Welfarism vs. extra-welfarism.
Journal of health economics 2008;27(2):325-38.
2008: Marten J Poley; Werner B F Brouwer; Jan J V Busschbach; Frans W J Hazebroek; Dick Tibboel; Frans F H Rutten; Jan C Molenaar
Cost-effectiveness of neonatal surgery: first greeted with scepticism, now increasingly accepted.
Pediatric surgery international 2008;24(2):119-27.
2008: W Ken Redekop; Ewa Orlewska; Pawel Maciejewski; Frans F H Rutten; Louis Niessen
Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.
PharmacoEconomics 2008;26(10):861-77.
2008: David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?
PharmacoEconomics 2008;26(10):815-30.
2008: Moniek C Vlasveld; Johannes R Anema; Aartjan T F Beekman; Willem van Mechelen; Rob Hoedeman; Harm W J van Marwijk; Frans F H Rutten; Leona Hakkaart-van Roijen; Christina van der Feltz-Cornelis
Multidisciplinary collaborative care for depressive disorder in the occupational health setting: design of a randomised controlled trial and cost-effectiveness study.
BMC health services research 2008;8():99.
2008: Siok Swan Tan; W Ken Redekop; Frans F H Rutten
Costs and prices of single dental fillings in Europe: a micro-costing study.
Health economics 2008;17(1 Suppl):S83-93.
2007: Carmen Galani; Heinz Schneider; Frans F H Rutten
Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland.
International journal of public health 2007;52(6):372-82.
2007: Marjoliek A IJff; Klaas M L Huijbregts; Harm W J van Marwijk; Aartjan T F Beekman; Leona Hakkaart-van Roijen; Frans F H Rutten; Jürgen Unützer; Christina van der Feltz-Cornelis
Cost-effectiveness of collaborative care including PST and an antidepressant treatment algorithm for the treatment of major depressive disorder in primary care; a randomised clinical trial.
BMC health services research 2007;7():34.
2007: Eva K Horn; Tjeerd B van Benthem; Leona Hakkaart-van Roijen; Harm W J van Marwijk; Aartjan T F Beekman; Frans F H Rutten; Christina van der Feltz-Cornelis
Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial.
BMC health services research 2007;7():28.
2006: Werner B F Brouwer; N J A van Exel; Rob Baltussen; Frans F H Rutten
A dollar is a dollar is a dollar--or is it?
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2006;9(5):341-7.
2006: Jan B Oostenbrink; Frans F H Rutten
Cost assessment and price setting of inpatient care in The Netherlands. the DBC case-mix system.
Health care management science 2006;9(3):287-94.
2006: N J A van Exel; Marc A Koopmanschap; Joseph McDonnell; Christopher Chapple; Richard Berges; Frans F H Rutten
Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study.
European urology 2006;49(1):92-102.
2005: Elly A Stolk; Frans F H Rutten
The "health benefit basket" in the Netherlands.
The European journal of health economics : HEPAC : health economics in prevention and care 2005;Suppl():53-7.
2005: Peter de Wolf; Werner B F Brouwer; Frans F H Rutten
Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?
The International journal of health planning and management 2005;20(4):351-74.
2005: Werner B F Brouwer; Louis Niessen; Maarten J Postma; Frans F H Rutten
Need for differential discounting of costs and health effects in cost effectiveness analyses.
BMJ (Clinical research ed.) 2005;331(7514):446-8.
2005: Raymond C W Hutubessy; Louis Niessen; Rob Dijkstra; Ton F Casparie; Frans F H Rutten
Stochastic league tables: an application to diabetes interventions in the Netherlands.
Health economics 2005;14(5):445-55.
2004: Leona Hakkaart-van Roijen; M B Hoeijenbos; EJ Regeer; Margreet ten Have; Willem A Nolen; C P W M Veraart; Frans F H Rutten
The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands.
Acta psychiatrica Scandinavica 2004;110(5):383-92.
2004: Pedram Sendi; Maiwenn J Al; Frans F H Rutten
Portfolio theory and cost-effectiveness analysis: a further discussion.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2004;7(5):595-601.
2004: Leona Hakkaart-van Roijen; Eric Moll van Charante; Patrick J E Bindels; C Joris Yzermans; Frans F H Rutten
A cost study of a general practitioner hospital in the Netherlands.
The European journal of general practice 2004;10(2):45-9.
2003: Werner B F Brouwer; Frans F H Rutten
The missing link: on the line between C and E.
Health economics 2003;12(8):629-36.
2003: Marc A Koopmanschap; Frans F H Rutten
The drug budget silo mentality: the Dutch case.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2003;6 Suppl 1():S46-51.
2003: Jan Paul Ouwens; Petra J van Enckevort; Elisabeth M TenVergert; Gauke J Bonsel; Wim van Der Bij; Elizabeth B Haagsma; Frans F H Rutten; Maarten J H Slooff; Gerard H Koëter
The cost effectiveness of lung transplantation compared with that of heart and liver transplantation in the Netherlands.
Transplant international : official journal of the European Society for Organ Transplantation 2003;16(2):123-7.
2003: Jan B Oostenbrink; Tineke Buijs-Van der Woude; Michel van Agthoven; Marc A Koopmanschap; Frans F H Rutten
Unit costs of inpatient hospital days.
PharmacoEconomics 2003;21(4):263-71.
2002: Frans F H Rutten; Werner B F Brouwer
[More care for a limited budget; a case for a better use of the efficiency criteria].
Nederlands tijdschrift voor geneeskunde 2002;146(47):2254-8.
2002: Katia M C Verhamme; Jeanne P Dieleman; Gysèle S Bleumink; Johan van der Lei; Miriam C J M Sturkenboom; W Artibani; B Begaud; Richard Berges; Andrzej Borkowski; C R Chappel; A Costello; Piotr Dobronski; Richard D T Farmer; F Jiménez Cruz; Udo Jonas; KD MacRae; Ludger Pientka; Frans F H Rutten; C P van Schayck; MJ Speakman; M C Sturkenboom; P Tiellac; A Tubaro; G Vallencien; R Vela Navarrete
Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.
European urology 2002;42(4):323-8.
2002: Werner B F Brouwer; N J A van Exel; Marc A Koopmanschap; Frans F H Rutten
Productivity costs before and after absence from work: as important as common?
Health policy (Amsterdam, Netherlands) 2002;61(2):173-87.
2002: Jan B Oostenbrink; Marc A Koopmanschap; Frans F H Rutten
Standardisation of costs: the Dutch Manual for Costing in economic evaluations.
PharmacoEconomics 2002;20(7):443-54.
2002: Joseph McDonnell; Angelique J Goverde; Frans F H Rutten; Jan P W Vermeiden
Multivariate Markov chain analysis of the probability of pregnancy in infertile couples undergoing assisted reproduction.
Human reproduction (Oxford, England) 2002;17(1):103-6.
2001: Marc A Koopmanschap; K C Touw; Frans F H Rutten
Analysis of costs and cost-effectiveness in multinational trials.
Health policy (Amsterdam, Netherlands) 2001;58(2):175-86.
2001: Werner B F Brouwer; Frans F H Rutten
Health economics. A bridge over troubled water.
European journal of public health 2001;11(2):234-6.
2001: C R Touw; Leona Hakkaart-van Roijen; Paul Verboom; Carle Paul; Frans F H Rutten; A Y Finlay
Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
The British journal of dermatology 2001;144(5):967-72.
2001: Leona Hakkaart-van Roijen; Paul Verboom; W Ken Redekop; K R Touw; Frans F H Rutten
The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis.
PharmacoEconomics 2001;19(5 Pt 2):599-608.
2001: R Jansen; W Ken Redekop; Frans F H Rutten
Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis.
PharmacoEconomics 2001;19(4):401-10.
2001: Joseph McDonnell; W Ken Redekop; N van der Roer; ES Goes; Annemieke Ruitenberg; Jan J V Busschbach; Monique Breteler; Frans F H Rutten
The cost of treatment of Alzheimer's disease in The Netherlands: a regression-based simulation model.
PharmacoEconomics 2001;19(4):379-90.
2001: C Chevat; B M Peña; Maiwenn J Al; Frans F H Rutten
Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.
PharmacoEconomics 2001;19 Suppl 1():17-32.
2001: Joseph McDonnell; Jan J V Busschbach; Esther T Kok; Job van Exel; Elly A Stolk; Marc A Koopmanschap; Frans F H Rutten
Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: health-economical analysis.
European urology 2001;39 Suppl 3():37-41.
2000: Louis Niessen; E W M Grijseels; Frans F H Rutten
The evidence-based approach in health policy and health care delivery.
Social science & medicine (1982) 2000;51(6):859-69.
2000: J E F Zwart-van Rijkom; Hubert G M Leufkens; Jan J V Busschbach; AW Broekmans; Frans F H Rutten
Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET Project.
PharmacoEconomics 2000;18(2):149-60.
2000: Frans F H Rutten
[Roaming through methodology. XIX. Cost-effectiveness ratios].
Nederlands tijdschrift voor geneeskunde 2000;144(27):1311-4.
2000: Christer Ehrnborg; Leona Hakkaart-van Roijen; Björn Jonsson; Frans F H Rutten; Bengt-Ake Bengtsson; Thord Rosén
Cost of illness in adult patients with hypopituitarism.
PharmacoEconomics 2000;17(6):621-8.
2000: Elly A Stolk; Jan J V Busschbach; M Caffa; E J Meuleman; Frans F H Rutten
Cost utility analysis of sildenafil compared with papaverine-phentolamine injections.
BMJ (Clinical research ed.) 2000;320(7243):1165-8.
2000: Elly A Stolk; H A Post; Frans F H Rutten; Jan C Molenaar; Jan J V Busschbach
Cost-effectiveness of neonatal surgery: a review.
Journal of pediatric surgery 2000;35(4):588-92.
2000: Angelique J Goverde; Joseph McDonnell; Jan P W Vermeiden; Roel Schats; Frans F H Rutten; Joop Schoemaker
Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis.
Lancet 2000;355(9197):13-8.
1999: Petra J van Enckevort; Elisabeth M TenVergert; J Kingma; Gerard H Koëter; Frans F H Rutten
Factors to consider when designing phase III clinical trials involving economic evaluations.
Perceptual and motor skills 1999;89(3 Pt 2):1059-72.
1999: Frans F H Rutten; E W M Grijseels
[Conditions for introduction and financing of new technologies].
Nederlands tijdschrift voor geneeskunde 1999;143(45):2229-32.
1999: Petra J van Enckevort; Elisabeth M TenVergert; S Schrantee; Frans F H Rutten; Elisabeth G E de Vries
Economic evaluations of systemic adjuvant breast cancer treatments: methodological issues and a critical review.
Critical reviews in oncology/hematology 1999;32(2):113-24.
1999: Werner B F Brouwer; Marc A Koopmanschap; Frans F H Rutten
Productivity losses without absence: measurement validation and empirical evidence.
Health policy (Amsterdam, Netherlands) 1999;48(1):13-27.
1999: M G Groener; B Martin van Ineveld; G Byttebier; B A van Hout; Frans F H Rutten
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
Anti-cancer drugs 1999;10(3):283-8.
1999: Werner B F Brouwer; N J A van Exel; Marc A Koopmanschap; Frans F H Rutten
The valuation of informal care in economic appraisal. A consideration of individual choice and societal costs of time.
International journal of technology assessment in health care 1999;15(1):147-60.
1998: Leona Hakkaart-van Roijen; A Beckers; Achille Stevenaert; Frans F H Rutten
The burden of illness of hypopituitary adults with growth hormone deficiency.
PharmacoEconomics 1998;14(4):395-403.
1998: Maiwenn J Al; BA van Hout; BC Michel; Frans F H Rutten
Sample size calculation in economic evaluations.
Health economics 1998;7(4):327-35.
1998: Carin A Uyl-de Groot; Bob Löwenberg; Edo Vellenga; Stefan Suciu; R Willemze; Frans F H Rutten
Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.
British journal of haematology 1998;100(4):629-36.
1998: Jan J V Busschbach; Werner B F Brouwer; A van der Donk; J Passchier; Frans F H Rutten
An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease.
PharmacoEconomics 1998;13(1 Pt 1):21-34.
1998: Werner B F Brouwer; Marc A Koopmanschap; Frans F H Rutten
Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel.
International journal of technology assessment in health care 1998;14(3):505-13.
1998: Petra J van Enckevort; Elisabeth M TenVergert; G J Bonsel; Albert Geertsma; Wim van Der Bij; Wim J de Boer; Marc A Koopmanschap; Maiwenn J Al; Frans F H Rutten
Technology assessment of the Dutch Lung Transplantation Program.
International journal of technology assessment in health care 1998;14(2):344-56.
1997: Carin A Uyl-de Groot; E Vellenga; E G de Vries; B Löwenberg; Gerrit Stoter; Frans F H Rutten
Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
PharmacoEconomics 1997;12(3):351-60.
1997: Werner B F Brouwer; Marc A Koopmanschap; Frans F H Rutten
Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.
Health economics 1997;6(5):511-4.
1997: Petra J van Enckevort; Marc A Koopmanschap; Elisabeth M TenVergert; Albert Geertsma; Wim van Der Bij; Wim J de Boer; Frans F H Rutten
Lifetime costs of lung transplantation: estimation of incremental costs.
Health economics 1997;6(5):479-89.
1997: A A van der Riet; B A van Hout; Frans F H Rutten
Cost effectiveness of DNA diagnosis for four monogenic diseases.
Journal of medical genetics 1997;34(9):741-5.
1997: BC Michel; P M Kuijer; Joseph McDonnell; Edwin J.R. van Beek; Frans F H Rutten; HR Büller
The role of a decision rule in symptomatic pulmonary embolism patients with a non-high probability ventilation-perfusion scan.
Thrombosis and haemostasis 1997;78(2):794-8.
1997: E Elsinga; Frans F H Rutten
Economic evaluation in support of national health policy: the case of The Netherlands.
Social science & medicine (1982) 1997;45(4):605-20.
1997: Werner B F Brouwer; Marc A Koopmanschap; Frans F H Rutten
Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.
Health economics 1997;6(3):253-9.
1996: Marc A Koopmanschap; Frans F H Rutten
The consequence of production loss or increased costs of production.
Medical care 1996;34(12 Suppl):DS59-68.
1996: Frans F H Rutten
[Pharmaco-economics and drug prices].
Nederlands tijdschrift voor geneeskunde 1996;140(45):2216-9.
1996: Marc A Koopmanschap; Frans F H Rutten
A practical guide for calculating indirect costs of disease.
PharmacoEconomics 1996;10(5):460-6.
1996: BC Michel; R J Seerden; Edwin J R Van Beek; Harry R Büller; Frans F H Rutten
[Costs of diagnosis and treatment for pulmonary embolism lower due to application of consensus strategy].
Nederlands tijdschrift voor geneeskunde 1996;140(37):1864-8.
1996: Maiwenn J Al; BC Michel; Frans F H Rutten
The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
PharmacoEconomics 1996;10(2):141-51.
1996: Carin A Uyl-de Groot; Peter C Huijgens; Frans F H Rutten
Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs.
PharmacoEconomics 1996;10(1):23-35.
1996: BC Michel; R J Seerden; Frans F H Rutten; Edwin J R Van Beek; Harry R Büller
The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism.
Health economics 1996;5(4):307-18.
1996: Edo Vellenga; Carin A Uyl-de Groot; R de Wit; H J Keizer; Bob Löwenberg; M A ten Haaft; Theo de Witte; C A Verhagen; Gerrit Stoter; Frans F H Rutten; Nanno H Mulder; w martin smid; Elisabeth G E de Vries
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):619-27.
1996: L van Roijen; Marie-Louise Essink-Bot; Marc A Koopmanschap; Gouke J Bonsel; Frans F H Rutten
Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire.
International journal of technology assessment in health care 1996;12(3):405-15.
1996: Carin A Uyl-de Groot; Edo Vellenga; Frans F H Rutten
An economic model to assess the savings from a clinical application of haematopoietic growth factors.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):57-62.
1995: Carin A Uyl-de Groot; Anton Hagenbeek; L F Verdonck; Bob Löwenberg; Frans F H Rutten
Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
Bone marrow transplantation 1995;16(3):463-70.
1995: L van Roijen; Marc A Koopmanschap; Frans F H Rutten; Paul J van der Maas
Indirect costs of disease; an international comparison.
Health policy (Amsterdam, Netherlands) 1995;33(1):15-29.
1995: Marc A Koopmanschap; Frans F H Rutten; B Martin van Ineveld; L van Roijen
The friction cost method for measuring indirect costs of disease.
Journal of health economics 1995;14(2):171-89.
1995: Marie-Louise Essink-Bot; L van Royen; P Krabbe; Gouke J Bonsel; Frans F H Rutten
The impact of migraine on health status.
Headache 1995;35(4):200-6.
1995: Carin A Uyl-de Groot; S Y Okhuijsen; Anton Hagenbeek; Peter C Huijgens; G W van Imhoff; Bob Löwenberg; L F Verdonck; Frans F H Rutten
Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.
Bone marrow transplantation 1995;15(4):605-10.
1995: A A van der Riet; P P Harteloh; Frans F H Rutten; J J Jonker
[Adjustment to insulin of patients with type II diabetes mellitus in primary care; good results at low cost].
Nederlands tijdschrift voor geneeskunde 1995;139(10):508-12.
1995: L van Roijen; Marie-Louise Essink-Bot; Marc A Koopmanschap; BC Michel; Frans F H Rutten
Societal perspective on the burden of migraine in The Netherlands.
PharmacoEconomics 1995;7(2):170-9.
1995: M M de Klerk; Robbert Huijsman; Frans F H Rutten
New options in long-term care for the elderly: evaluation results of demonstration projects in The Netherlands.
Home health care services quarterly 1995;15(2):19-40.
1994: Robbert Huijsman; G Wielink; M M de Klerk; H Rigter; Frans F H Rutten
[Effect of physical activity in the elderly: a review of current literature and the possibility of economic evaluation].
Tijdschrift voor gerontologie en geriatrie 1994;25(6):237-49.
1994: C N Hilgeman; Marc A Koopmanschap; Frans F H Rutten
[Costs of intensive care in The Netherlands].
Nederlands tijdschrift voor geneeskunde 1994;138(45):2252-6.
1994: Marc A Koopmanschap; Frans F H Rutten
The impact of indirect costs on outcomes of health care programs.
Health economics 1994;3(6):385-93.
1994: B A van Hout; Maiwenn J Al; G S Gordon; Frans F H Rutten
Costs, effects and C/E-ratios alongside a clinical trial.
Health economics 1994;3(5):309-19.
1994: Carin A Uyl-de Groot; Frans F H Rutten
[Costs of autologous bone marrow transplantation in non-Hodgkin lymphoma and acute leukemia].
Nederlands tijdschrift voor geneeskunde 1994;138(1):28-31.
1994: Carin A Uyl-de Groot; Frans F H Rutten; Gouke J Bonsel
Measurement and valuation of quality of life in economic appraisal of cancer treatment.
European journal of cancer (Oxford, England : 1990) 1994;30A(1):111-7.
1994: B A van Hout; E Birnie; W K Redekop; R H Lorijn; Patrick Bossuyt; Frans F H Rutten
Cost-effectiveness of HA-1A treatment for patients with sepsis.
Progress in clinical and biological research 1994;388():435-43.
1994: Carin A Uyl-de Groot; D J Richel; Frans F H Rutten
Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation.
European journal of cancer (Oxford, England : 1990) 1994;30A(11):1631-5.
1994: Carin A Uyl-de Groot; Gert Ossenkoppele; A A van Riet; Frans F H Rutten
The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.
European journal of cancer (Oxford, England : 1990) 1994;30A(4):457-9.
1993: Marc A Koopmanschap; Frans F H Rutten
Indirect costs in economic studies: confronting the confusion.
PharmacoEconomics 1993;4(6):446-54.
1993: C K Schipper; Frans F H Rutten; R J Loffeld
[Costs and effectiveness of diagnosis and treatment of patients with dyspepsia, determined with the aid of a computer model].
Nederlands tijdschrift voor geneeskunde 1993;137(35):1767-71.
1993: B A van Hout; G Wielink; Gouke J Bonsel; Frans F H Rutten
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.
PharmacoEconomics 1993;3(5):387-97.
1993: B A Van Hout; Frans F H Rutten; R H Lorijn
[Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].
Nederlands tijdschrift voor geneeskunde 1993;137(7):360-4.
1993: Gouke J Bonsel; Frans F H Rutten; Carin A Uyl-de Groot
Economic evaluation alongside cancer trials: methodological and practical aspects.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 7():S10-4.
1991: L L Martens; Frans F H Rutten; J L Kuijpens; J Winter
[Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
Nederlands tijdschrift voor geneeskunde 1991;135(15):655-9.
1990: L L Martens; Frans F H Rutten; D W Erkelens; C A Ascoop
Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.
The American journal of cardiology 1990;65(12):27F-32F.
1989: L L Martens; Frans F H Rutten; D Willem Erkelens; C A Ascoop
Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine.
The American journal of medicine 1989;87(4A):54S-58S.